PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Experimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge, UK.\', \'Division of Experimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge, UK. mf503@medschl.cam.ac.uk.\', \'Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. mf503@medschl.cam.ac.uk.\', \'Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.\', \'Cambridge Clinical Trials Unit, University of Cambridge, Cambridge, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04543-4
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 32616067
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32616067>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32616067>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all